Jetrea ocriplasmin: Phase II started

ThromboGenics began the double-blind, placebo-controlled, international Phase II CIRCLE trial to evaluate up to 3 intravitreal injections of 0.0625 and 0.125 mg ocriplasmin in 230 patients with non-pr...